Featured Stories

Charles River Acquires BRASS Pte Ltd

10/07/2013

Charles River is pleased to announce that it has acquired BRASS Pte Ltd (“BRASS”). Building on the partnership established with BRASS in 1997, Charles River aims to accelerate the growth of its portfolio of products and services in Asia by providing clients with state-of-the-art microbial detection and identification for manufacturing in the biopharmaceutical, medical device and life sciences industries.

Hamster Hypercholesterolemia Model Now Available

10/07/2013

The Golden Syrian hamster is a well-established species for the study of lipoprotein profiles. It translates to human outcomes because the species carries the cholesteryl ester transfer protein (CETP). 

New Hires Expand Pathology Expertise

09/09/2013

We are pleased to welcome Dr. Wendell Davis, former Director and Head of the Comparative Pathology and Discovery Toxicology at Biogen Idec, and Dr. Matthew Smith, former veterinary pathologist at Bristol-Myers Squibb, to Charles River. Their collective experience and knowledge of the industry adds significant value to our pathology team.

Refinement in Dual Catheterization Surgical Procedure

09/02/2013

We have made changes to our standard dual catheterization surgical procedure so that both catheters exit a single midline incision. By using one exit point, we will reduce any unnecessary trauma to the model. 

Four New Rodent Pain Models Now Available

08/28/2013

Our new pain models focus on neuropathic, inflammatory and chronic joint pain indications and provide quantitative behavioral endpoints for developing new pain medications.  They assist researchers in assessing and increasing translatability between discovery and first-in-human studies.

Displaying results 1-10 (of 80)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8  >  >|